Nucor earnings beat by $0.08, revenue fell short of estimates
Tuesday, SI-BONE Inc. (NASDAQ:SIBN) received continued support from Cantor Fitzgerald, as the firm reiterated its Overweight rating and $25.00 price target. The endorsement follows SI-BONE’s announcement of its first-quarter financial results for 2025 and an increase in the higher end of its full-year revenue forecast. According to InvestingPro data, the company maintains a "GOOD" financial health score, with a strong current ratio of 7.66 and more cash than debt on its balance sheet.
SI-BONE reported first-quarter revenue of $47.3 million, surpassing both Cantor Fitzgerald’s projection of $45.1 million and the FactSet consensus, which was also $45.1 million. This figure represents a year-over-year growth of approximately 25%, continuing the company’s strong growth trajectory, with trailing twelve-month revenue growth at 20.37% and an impressive gross profit margin of 79.03%. The company’s active U.S. surgeon count rose to over 1,400, marking a 27% growth from the previous year.
The firm’s sales representatives were also noted for their productivity, each generating around $2.0 million in the quarter, a 25% increase year-over-year. These financial indicators are part of the rationale behind Cantor Fitzgerald’s positive outlook on the company.
Looking ahead to the rest of 2025, Cantor Fitzgerald expressed confidence in SI-BONE’s potential to exceed expectations. The firm’s optimism is based on SI-BONE’s expanding product portfolio and its early success in driving adoption within the interventional community. This success is reflected in the strong year-over-year revenue growth of 27% for the first quarter, which is significantly higher than the growth rate of the spinal implant market. InvestingPro analysis shows analyst targets ranging from $19 to $32, with additional insights available in the comprehensive Pro Research Report.
Cantor Fitzgerald highlighted the stock’s value, noting that SI-BONE shares are trading at 2.5 times the calendar year 2025 estimated enterprise value to revenue. This is compared to a 4.0 times multiple for the company’s high-growth MedTech peers. The firm’s reiteration of the Overweight rating on SI-BONE is grounded in these financial metrics and market comparisons. However, InvestingPro’s Fair Value analysis suggests the stock is currently overvalued, with three analysts recently revising their earnings expectations downward for the upcoming period.
In other recent news, SI-BONE Inc. reported its first-quarter 2025 earnings, showcasing a notable financial performance. The company achieved revenue of $47.3 million, surpassing the projected $45.13 million and marking a 25% year-over-year increase. This strong revenue performance led to a positive adjusted EBITDA of $0.5 million, significantly exceeding the anticipated $2.6 million loss. Following these results, SI-BONE raised its annual revenue guidance, with the midpoint now indicating expected growth of 17% year-over-year.
Analysts at JMP Securities maintained their Market Outperform rating for SI-BONE, with a price target of $32.00, reflecting confidence in the company’s financial health and growth potential. The company’s U.S. revenue increased by 26.6%, contributing to a gross profit of $37.7 million and a gross margin of 79.7%. SI-BONE also plans to launch a new SI joint fusion solution in early 2026, aiming to expand its market position further.
The company continues to focus on innovation, engagement, and operational excellence, expecting to maintain positive adjusted EBITDA throughout 2025. SI-BONE’s strategy includes leveraging its hybrid commercial infrastructure to drive productivity and expand its reach, with plans to increase its U.S. territories over the next year. These developments underscore SI-BONE’s robust growth trajectory and strategic positioning in the medical technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.